L-Arginine (Cardiovascular).

Citrulline is converted to arginine by kidney argininosuccinate synthase and lyase and avoids the intestinal arginase that clears much of an oral arginine dose. Combining them gives an immediate rise plus a sustained one.

Endothelial nitric oxide synthase needs tetrahydrobiopterin to stay coupled, and ascorbate keeps that cofactor reduced. Without it the enzyme produces superoxide instead of using arginine well.

5-methyltetrahydrofolate supports regeneration of tetrahydrobiopterin and lowers homocysteine, which otherwise raises the NOS inhibitor ADMA. Both effects act on the same enzyme arginine feeds.

Pine bark polyphenols support endothelial nitric oxide synthase activity and reduce oxidative loss of nitric oxide. Arginine supplies the substrate, the polyphenol supports the enzyme and the product.

EPA and DHA change endothelial membrane composition and eicosanoid balance, which affects nitric oxide synthase behaviour from the lipid side. Arginine acts on the substrate side of the same enzyme.

CoQ10 supports mitochondrial electron transport and limits the superoxide that reacts with nitric oxide and shortens its life. Arginine determines how much nitric oxide can be made in the first place.

Magnesium restrains calcium entry into vascular smooth muscle, which supports normal vessel relaxation, and it is the cofactor for the ATP-dependent steps around nitric oxide signalling. Arginine works on the nitric oxide side of the same tone.

Taurine supports the endothelial redox environment and cardiac calcium handling while arginine supplies the nitric oxide substrate. The two act on separate parts of normal vascular tone.

Garlic organosulfur compounds support nitric oxide production and generate hydrogen sulfide, a second vasodilator signal that interacts with nitric oxide. Arginine feeds the enzyme route directly.

Lysine and arginine both move on the y+ cationic amino acid transporters, so lysine in the same serving competes for arginine absorption and cellular entry. Settled transport pharmacology that belongs on any arginine label.

Dietary nitrate is reduced to nitrite and then nitric oxide without an enzyme substrate, working well where oxygen is low, while arginine works through nitric oxide synthase. The two routes cover different conditions.

Norvaline inhibits arginase, which otherwise diverts arginine into ornithine and urea. Restraining that route leaves more arginine available to nitric oxide synthase.

Arginine hands its amidino group to glycine through AGAT to form guanidinoacetate on the way to creatine. This is a settled competing use of arginine that a formula should account for.

Enterocytes convert glutamine to citrulline, the kidney converts citrulline to arginine, and that intestinal-renal axis supplies a large share of circulating arginine outside the diet. Supplying glutamine therefore feeds the same pool that arginine supplementation targets, upstream of the first-pass arginase losses that limit oral arginine. The combination has been used in perioperative nutrition formulas alongside HMB. The pathway is textbook; the clinical add-on effect is what varies by setting.

Arginase splits arginine into urea and ornithine, and ornithine transcarbamylase carries ornithine back toward citrulline and then arginine. The two amino acids sit on opposite ends of the same cycle, so supplying ornithine loads the recycling arm rather than the nitric oxide arm. Ornithine also feeds polyamine and proline synthesis, which is a different destination from nitric oxide production. Which arm dominates depends on arginase activity in the tissue.

Arginine donates its amidino group to glycine to make guanidinoacetate, which is then methylated to creatine using S-adenosylmethionine. Supplying creatine directly reduces the demand this pathway places on the arginine pool. Animal work on guanidinoacetate supplementation reinforces the same pathway from the other end. In practice the pairing shifts arginine availability toward other uses rather than adding two independent effects.

Guanidinoacetate methyltransferase is one of the largest consumers of methyl groups in the body, and those methyl groups come from S-adenosylmethionine derived from methionine. Pushing the arginine-to-creatine route therefore draws on methionine and raises homocysteine output from that transfer. The link is stoichiometric, not speculative. It is a reason the pairing is usually discussed with the B vitamins that recycle homocysteine.

Betaine donates a methyl group to homocysteine through betaine homocysteine methyltransferase, regenerating methionine and supporting the S-adenosylmethionine pool that the creatine synthesis step consumes. Since that step is fed by arginine, betaine sits directly downstream of arginine flux. Homocysteine itself is an association marker for vascular measures, not a demonstrated causal target. The relationship here is metabolic and well characterised.

Pyridoxal-5-phosphate is the cofactor for cystathionine beta-synthase and cystathionine gamma-lyase, the enzymes that clear homocysteine down the transsulfuration route. It is also the cofactor for the transaminases that move nitrogen between amino acids, including the ornithine aminotransferase step adjacent to the urea cycle. Supplying arginine increases traffic through those junctions. The cofactor relationship needs no trial to be stated.

Methionine synthase requires methylcobalamin to remethylate homocysteine back to methionine using a methyl group from folate. That regeneration supports the methyl pool the arginine-to-creatine step draws down. Without adequate B12 the folate-dependent arm of this cycle stalls regardless of how much methyl donor is supplied elsewhere. This is settled cofactor biochemistry.

HMB, arginine and glutamine are combined in a widely used clinical nutrition blend, and the combination has been studied on inflammatory markers in surgical patients. The measured endpoints in that work are circulating markers rather than clinical outcomes. The three components act through different routes, so the pairing is additive by design rather than mechanistically synergistic. Read the marker data as marker data.

Endothelial nitric oxide synthase needs tetrahydrobiopterin to couple arginine oxidation to nitric oxide production; when that cofactor is oxidised the enzyme uncouples and makes superoxide instead. Alpha-lipoic acid maintains a reducing environment that helps keep biopterin in its active form. Supplying arginine without cofactor support can push an uncoupled enzyme harder. The cofactor requirement is established; the supplementation effect on it is promising rather than settled.

Nitric oxide reacts rapidly with superoxide to form peroxynitrite, which removes the signalling molecule and damages lipids. Alpha-tocopherol terminates lipid peroxidation chains in the membrane where that reaction happens. The pairing rationale is mechanistic and the human combination data are thin. Read it as mechanism rather than as a demonstrated combined effect.

Cysteine thiols react with nitric oxide to form S-nitrosothiols, which act as a transportable reservoir of nitric oxide activity. N-acetylcysteine supplies cysteine for that chemistry and for glutathione synthesis. Whether supplementing it changes vascular measures alongside arginine is not established in trials. The chemistry is solid, the clinical translation is not.

Resveratrol has been shown in cultured endothelial cells and animal models to increase eNOS expression and activity. Arginine supplies the substrate that enzyme uses. Pairing a substrate with something that acts on enzyme abundance is mechanistically coherent, but the human evidence for the combination has not been established. The animal and cell weighting should be stated whenever this pairing is described.

Arginase competes with nitric oxide synthase for arginine, and several flavonoids including quercetin have been reported to reduce arginase activity in preclinical models. Less arginase traffic leaves more substrate for the nitric oxide route. This is cell and animal evidence and has not been carried into a human combination trial. It belongs in the early band.

Potassium supports normal vascular smooth muscle relaxation and endothelium-dependent dilation through membrane potential effects, a route separate from nitric oxide substrate supply. Combining the two touches the same endpoint from two directions, so anyone tracking blood pressure should be aware the effects can add. Both are ordinary dietary components rather than pharmacological agents. The additive direction is what matters for formulation rather than any single mechanism.

Carnitine supports mitochondrial fatty acid transport and appears alongside arginine in cardiovascular nutrition research and in amino acid supplementation reviews. The two act on different steps and there is no shared enzyme or transporter of note. Any combined effect would be additive rather than mechanistic. Evidence for the pairing specifically is early.